Wuhan Easy Diagnosis Biomedicine
Launch date
Employees
Market cap
$501m
Enterprise valuation
$389m (Public information from Sep 2024)
Share price
CNY15.46 002932.SZ
Wuhan Hubei (HQ)
Financials
Estimates*
| CNY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | - | 181m | 959m | 2.8b | 10.5b | 750m |
| % growth | - | - | 429 % | 195 % | 272 % | (93 %) |
| EBITDA | - | 64.0m | 581m | 1.7b | 6.2b | 304m |
| % EBITDA margin | - | 35 % | 61 % | 62 % | 58 % | 41 % |
| Profit | - | 41.5m | 469m | 1.4b | 4.2b | 74.9m |
| % profit margin | - | 23 % | 49 % | 50 % | 40 % | 10 % |
| EV / revenue | - | 11.3x | 3.8x | 2.1x | 0.4x | 5.5x |
| EV / EBITDA | - | 31.9x | 6.2x | 3.4x | 0.8x | 13.6x |
| R&D budget | - | 37.0m | 69.9m | 133m | 388m | 141m |
| R&D % of revenue | - | 20 % | 7 % | 5 % | 4 % | 19 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
